AdvanCell

AdvanCell announced $315M in Series D financing on July 15, 2026. AdvanCell closed an oversubscribed, upsized $315 million Series D led by Ally Bridge Group and co-led by Alpha Wave to advance ADVC001 toward Phase 3 and expand U.S. manufacturing.

Round details

The financing includes backing from Ally Bridge Group, Alpha Wave, Bain Capital Life Sciences, Fidelity Management and Research Company, T. Rowe Price Associates, Eli Lilly and Company, Sanofi Ventures, Morningside. The company did not publish a valuation with the announcement.

• Round: Series D
• Capital announced: $315M

How the company plans to use the capital

AdvanCell said the financing will advance ADVC001 toward Phase 3 clinical development in metastatic prostate cancer. It will also expand U.S. manufacturing infrastructure to support Phase 3 development and future commercial demand, and accelerate the company’s pipeline of targeted alpha therapies.

Why this matters for GTM teams

The financing pairs clinical development of ADVC001 toward Phase 3 with an expansion of U.S. manufacturing infrastructure in a single round.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: AdvanCell Series D announcement.